Introduction
Most women with epilepsy (WWE) can, with careful planning of pregnancy and management of delivery, expect a normal pregnancy outcome. Antiepileptic drug therapy is generally sustained in pregnancy, due to potential harm of uncontrolled generalised tonic-clonic seizures and to assure good maternal and foetal health. Pharmacokinetic changes associated with pregnancy can decrease the serum concentration of several antiepileptic drugs (AEDs), especially lamotrigine. Therapeutic drug monitoring is recommended for pregnant women using these drugs and dose escalation is commonly required in order to maintain a therapeutic serum concentration. Consequently, dose reduction after birth is necessary. 1, 2 Balanced medicines information regarding the risks and benefits of AEDs is important to reduce unnecessary concerns regarding drug treatment and for pregnant women's participation in therapeutic decisions. 1 Others have documented that pregnant women, including those with epilepsy, have needs for information about teratogenic risks of medicines. [3] [4] [5] [6] Medicines information sources frequently used by pregnant women include health care professionals, written material (e.g. patient information leaflets, PILs), family or friends, 5, 7 and the Internet. 8, 9 However, medicines information on the Internet may be both inconsistent and of varying quality, and may lead to increased and unjustified concern when used as sole information source. 8 Teratology information services (TIS) and medicines or drug information centres (DICs) are available to pregnant and breast-feeding women in several countries and have been shown to prevent congenital malformations and unnecessary pregnancy terminations. 10, 11 Both pregnant women and their health care providers have been shown to overestimate teratogenic risks, possibly resulting in inadequate treatment or unjustified termination of pregnancies. 12 , 13 We can expect that pregnant WWE have several concerns as to how the disease and the use of AEDs may affect their unborn children. WWE have more fear of pregnancy and childbirth, mainly due to concerns about malformations and pain, 14 and have a higher incidence of postpartum depression compared to pregnant women without epilepsy. 15 Pregnant WWE therefore have some distinct features which could influence risk perception, and possibly also medicines information needs, compared to pregnant women in the general population. However, we have not found any previous studies exploring these issues among pregnant WWE. The purpose of the present study was therefore to examine risk perceptions and needs for medicines information in pregnant WWE.
Methods

Design
Qualitative, semi-structured and individual in-depth interviews.
Recruitment of participants
Women who met the following criteria were eligible for the study:
Diagnosed with epilepsy and treated with one or more AEDs. Patient at the neurology outpatient clinic, either at Haukeland University Hospital in Bergen, Norway, or at Oslo University Hospital in Oslo, Norway. Undergone 18 weeks' pregnancy routine ultrasound screening without any teratogenic effects observed. 18 years of age or older.
A nurse or a neurologist at the outpatient clinic invited pregnant women who met the inclusion criteria to participate and gave them a letter of information about the study. The women who accepted participation were either contacted by the researcher (SFW) or the nurse to schedule the interview. At both neurology clinics, there were well-established and defined schedules for follow-up of pregnant WWE. These schedules include preconception counselling and regular counselling during pregnancy at the neurology clinic, ultrasound examination at 11-14 weeks' gestation and expanded ultrasound examination at 18 weeks' gestation, in addition to obstetric follow-up according to individual plans. 16 Participants were recruited during the following periods: October to December 2008 (from Haukeland University hospital only) and November 2009 to September 2010 (from both hospitals). The sample was opportunistic. A strategic sample was not possible due to the limited number of eligible women during the period of data collection. The exact number of interviews was determined along the way, based on stepwise analysis after every third to fourth interview.
Data collection
All women were interviewed at the neurology clinic for approximately 1 h. Reimbursement was offered for travel expenses. The interviews were initiated with a short questionnaire where the participants were asked to provide information regarding their age, week of gestation, type of seizure, present seizure frequency, number of years since the diagnosis was set, number of previous children and use of AEDs and other medicines ( Table 1 ). The interview guide was semi-structured and contained open-ended questions regarding the women's:
Risk perception: experiences and thoughts on using medicines and risking seizures in pregnancy, in addition to physicians' presentation of teratogenic risks. Experiences with and needs for medicines information, including participation in decisions regarding therapeutic drug regimens and relations with the health care system.
Analysis
Author SFW performed, audiotaped, and transcribed the interviews verbatim. The process of analysis was facilitated by use of the text analysis software NVivo, version 9 (QRS International Pty Ltd). The analysis was performed in accordance with the principles of systematic text condensation, a four step process. 17 In the first step, the transcripts were read by all three authors to identify recurring themes within the transcripts. Six recurring themes were initially identified: mastering life with a chronic disease, relations to the health care system, experience with and needs for medicines information, risk perception and risk assessment, attitude to taking medicines and concerns during pregnancy, labour and postpartum-period. In the second step, the transcripts were analysed iteratively according to these themes.
Step three involved further condensing and abstracting the text for its contents into subgroups and describing the content of each subgroup with an artificial quote. In the final step, the content of each subgroup was abstractly described and the contents of the subgroups were compared to the original transcripts. This step was performed by authors SFW and AGG. According to the aims of the study, all three authors defined the categories for presenting the results as (1) risk perception and (2) experience with and needs for medicines information. Quotes from the women were used to illustrate the results.
Preconceptions
This study was based on a medicines information perspective. The first and second author (SFW and JS) work in a regional medicines information and pharmacovigilance centre (DIC), 11 counselling both health care professionals and pregnant or breast- feeding women regarding teratogenic risks. The last author (AGG) has worked with medication reviews and drug-related problems in nursing homes and general practice, and studied patients' understanding and beliefs about medicines. 18 Our experience was the basis for studying medicines information needs and risk perception from a patient perspective. Pregnant WWE were chosen as the study population as both this chronic disease and the drug treatment represent possible risks to foetal health. We considered a qualitative interview most appropriate to explore personal experiences according to the aims of the present study.
Ethics
The study was approved by the Regional Committee for Medical Research Ethics and The Norwegian Social Science Data Services. Informed consent was given by the participants and the work has been carried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki).
The interviewer answered questions regarding for example the content and administration of drugs, but was cautious not to interfere with therapy or to induce worries regarding drug use in pregnancy. The women were encouraged to contact the interviewer in case of emerging issues after the interview.
Results
Background information on participants
Ten women of Caucasian ethnicity, aged 22-39 years in 20-34 weeks' gestation, participated in the study. Only one or two invited women refused participation. Demographic and epilepsy-or pregnancy-related characteristics of the participants are presented in Table 1 .
Risk perception
All participants stated that the benefits of taking AEDs to avoid seizures in pregnancy clearly outweighed teratogenic risks. Consequently, self-reported adherence to AED therapy was high, and some women reported to be even more attentive to taking AEDs during pregnancy: ''I haven't forgotten to take the medicine while I've been pregnant, but it has happened before. It doesn't happen often, but when taking medicines for so many years you are bound to miss out sometimes.'' (Participant 7). A few of the women stated that having a child would not be possible without accepting use of AEDs. Nevertheless, some expressed concerns for taking medicines during pregnancy. Several women reported that their neurologist had imparted low teratogenic risks of AEDs, though they could not be ruled out, balancing these risks against the risk of seizures.
The women were concerned for teratogenic effects as a result of increasing the dose of AEDs during pregnancy. This was of particular concern when dose escalation took place in large steps, compared to regular, small increases. Also, reducing the dose after childbirth caused concern, due to risks of triggering seizures. A few reported that their neurologist had explained the basis for dose adjustments associated with pregnancy, but apparently this counselling had little influence on perceived teratogenic risks.
Important factors for reducing concerns regarding teratogenic effects of AEDs included ultrasound examinations during early pregnancy and regular controls of foetal heart rates and movements throughout pregnancy. Also, preconception counselling, aiming to find the optimal AED therapy, reduced concerns. The women who already had given birth to healthy children reported a lower risk perception regarding possible negative effects compared to nulliparous women: ''I think about all that my baby is exposed for, but I have two healthy children even though I used medicines then, so I have a positive attitude to it.'' (Participant 3). Furthermore, hearing about successful pregnancies among other women using AEDs was reassuring. In addition, women with a long-standing diagnose of epilepsy coped better with concerns about the risks of AEDs and seizures whilst pregnant compared to recently diagnosed women.
Most women had a restrictive attitude to taking other medicines than AEDs in pregnancy. When experiencing symptoms such as nausea, headache or hay fever during pregnancy, the benefits of taking an additional medicine had to be prominent, even with safe medicines, such as acetaminophen for headache or antihistamines against seasonal allergy. ''I've had some pain lately and pushed my limits quite far before I've taken one tablet of acetaminophen. I've had to do it, but I'd rather not.'' (Participant 8).
Experiences with and needs for medicines information
The participating WWE were satisfied with the amount of medicines information provided and reported limited needs for medicines information due to long-standing use of AEDs and to restrictive use of other medicines. Despite this, the women appreciated medicines information both in written form and through oral communication with health care professionals, as supplement to each other.
The women expressed trust in physicians in general, and in their neurologist in particular. This credibility was further enhanced when the physician took the time to explain medical issues and answering questions, demonstrating professional competence by referring to conference attendance, or by consulting the medical literature or a specialist colleague during consultations. The women regarded the neurologist as their primary source of information regarding AEDs and one woman stated the following: ''It's really important for me to have the same person to relate to. . . who knows me and has followed me all the way. A family physician has just a fraction of the knowledge in that field.'' (Participant 10). Co-operation between the woman and her neurologist was demonstrated by the woman communicating the need for therapy adjustment when adverse effects or seizure frequency affected her quality of life or social life.
Most women browsed the Internet for health-and pregnancy related information in general, although a few were determined not to use the Internet at all while pregnant. The Internet was presented as an instant, superficial source of information with inherent problems of inconsistencies and varying quality of information. ''I have searched the Internet, that was the first thing I did, though different sites give so much different information. Not all of it is good for you to read.'' (Participant 9).
PILs were especially consulted by the women at initiation of a medicine or experience of new symptoms suspected to be adverse effects. A challenge with PILs was that texts were perceived as difficult to interpret.
The women were exceptionally satisfied with the follow-up provided by the health care system: ''I'm very impressed by the follow-up that is offered here at the hospital when you're pregnant and have epilepsy; they deserve much credit for that.'' (Participant 7). Satisfaction included follow-up from neurologists and epilepsy nurses at the outpatient neurology clinics and from gynaecologists and midwives at the Department of Gynaecology and Obstetrics. Continuity of health care personnel at follow-ups increased satisfaction.
Discussion
To our knowledge, this is the first study to describe medicines information needs according to teratogenic risk perceptions in pregnant WWE. Our findings suggest that pregnant WWE accept inherent teratogenic risks of AEDs to reach therapeutic goals during pregnancy, although dose adjustments during and after pregnancy increase the perceived risks of teratogenicity or seizures. In the following, our findings will be discussed to formulate suggestions for medicines information strategies to pregnant WWE.
Risk perception
The women viewed AEDs as beneficial due to their seizurepreventing effects and reported a high level of adherence to AED treatment. The connection between beneficial beliefs about medicines and adherent behaviour has been confirmed by others. 19, 20 A high level of adherence could also be explained by a trusting patient-physician relationship, chronic use of AEDs and motivation to self-control of the disease. 21, 22 Despite their beneficial beliefs regarding AEDs, the women were concerned for having to take them. In line with this, others have reported concerns for teratogenic effects of AEDs and other pregnancyrelated risks among patients with epilepsy.
23-25
The women had a restrictive attitude to use of other medicines than AEDs, including those regarded as safe in pregnancy. In a Norwegian study, almost 90% of pregnant women reported to have a higher threshold for using medicines as pregnant compared to non-pregnant. 26 The attitudes towards use of medicines of the women participating in our study therefore appeared not to differ substantially from those of pregnant women in general. However, one possible explanation for our findings could be that WWE compensate for the use of AEDs in pregnancy by avoiding other medicines due to a belief that teratogenic risk is additive in relation to the number of drugs used. An exaggerated restrictive attitude to medicines use in pregnancy could have consequences since untreated symptoms in pregnancy may have negative influence on the health of the mother and foetus. 13 Insufficient provision of medicines information could be an alternative explanation for the women's unwillingness to use necessary medicines regarded as safe in pregnancy. Insufficient medicines information was not brought up by the women, but we speculate that providing further information regarding the safety and benefit of medicines for treatment of symptoms other than epilepsy, could result in improved health for mother and foetus.
Our results indicate that information regarding the need for dose escalation of AEDs during pregnancy, and consequently, dose reduction after birth, is essential in order to normalize the risk perception of teratogenicity or seizures. We speculate that the women considered dose adjustments to be a sign of a poorly controlled disease, and had limited knowledge of the reasons for dose adjustments. However, from a neurologists view, dose adjustments of AEDs in pregnancy are part of providing optimal seizure control. Neurologists and other physicians should strive to fill the gap between their knowledge and the perceptions of pregnant WWE. We suggest dose adjustments to be explained both in preconception planning and during follow-up visits during pregnancy.
Previous positive experiences with pregnancy and experiences of family or friends are weighed in the process of risk assessment in pregnancy. 27, 28 One possibility is to arrange support groups where WWE who have experienced pregnancy and giving birth while using AEDs can support nulliparous WWE. With such support groups, the inexperienced women could get a realistic impression of risks during pregnancy, childbirth and postpartum. In support of this suggestion, others have found that patients with epilepsy appreciate meeting others with the disease for interaction and sharing of advice. 24 
Experience with and needs for medicines information
Confidence in information provided by health care providers, as suggested by our study findings, is important for teratogenic risk counselling and may influence how risks are perceived. 29, 30 Trust was especially evident in the patient-neurologist relationship, suggesting a high impact of the neurologist as medicines information provider. In particular, balanced presentations of benefits and risks, both of AEDs and other medicines, could support realistic teratogenic risk perceptions and rational medicines use in WWE. This presentation should ideally be given when a woman is considering pregnancy. 25 The WWE in our study took active part in the management of their disease, in co-operation with their neurologist. This suggests that the women preferred shared decision making, which is the preferred model of decision making by patients in general. 31, 32 The women were in general satisfied with the amount of medicines information provided, but reported concerns for when dose adjustments of AEDs were performed during and after pregnancy, pointing to an uncovered area of medicines information. Thus, the quality of medicines information to WWE could be improved by targeting specific areas of concern. The needs for additional medicines information were described as limited by the participating women and could be interpreted as medicines information needs reaching a saturation point. In line with the findings of others, this may be a natural consequence of chronic medicines use. 33, 34 Nevertheless, since patients with chronic diseases in general are encouraged to take an active role in the management of their disease, sufficient provision of medicines information is important 35 and specific information should be repeated and updated. However, whereas information increases empowerment in some patients, it increases concerns and diminished confidence in therapies in others. 33, 34 This emphasizes the need for tailoring medicines information according to individual needs and risk perceptions. Aiming to inform patients about specific changes in drug therapy or the state of the disease, and not just provide general information is pivotal for achieving these goals. 34 The participants appreciated both oral and written medicines information, consistent with the research of others. 34, 36 As suggested by our results, the language of written information, such as PILs, is important for understanding and interpretation and should be taken into account when formulating medicines information. 37 One strategy could be to provide easy-understandable, quality-controlled, and preferably tailored, medicines information through websites for hospitals or epilepsy-patient associations. Nevertheless, having the opportunity to elaborate on written medicines information is essential, and important for adjusting information according to individual needs. 38 Individualized medicines information should be offered both from health care professionals and through TIS and similar services for pregnant women.
Methodological considerations
In the recruitment process, we could not include WWE who theoretically could have been pregnant, but had avoided pregnancy due to poorly regulated epilepsy or disabilities. Furthermore, women carrying a foetus diagnosed with a teratogenic effect were excluded due to ethical issues. These WWE could have different risk perceptions compared to the included women, but could be influenced by situational anxiety. Thus, to formulate general statements regarding needs for medicines information based on a limited sample of WWE, we decided to recruit the women after they had gone through the 18 weeks' routine ultrasound examination. Furthermore, reliance on ultrasound examinations and other measures of fetal well-being in pregnancy, as means of reducing WWE's concerns for teratogenicity, would not be expected to carry such weight preconceptionally, in early pregnancy or after an abnormal scan. Performing the interviews at an earlier stage of pregnancy may have given less consistent findings because the women would lack sufficient time to reflect over and experience medicines use and information needs during pregnancy. Participants were all Caucasian and including women with different ethnicity could enrich the sample and be valuable for comparison. On the other hand, with a limited sample of WWE, we consider it to be a strength that the participants were of homogenous ethnicity. A final possible selection bias was that relations with the recruiter could have influenced the woman's willingness to participate.
The present results are not directly transferable to all pregnant WWE. Our included women took part in the followup program for pregnant WWE offered through Norwegian hospitals. The results may therefore not be valid in a population of pregnant WWE outside this follow-up program, who also may differ in their type of seizures and use of AEDs. However, we included women from two neurology clinics located at university hospitals in different cities and women who varied in their type of seizures, age, parity and number of years since diagnosis. Based on this, we believe that the findings of this study could be applied on pregnant WWE in similar countries with similar health care systems, follow-up systems and access to medicines information. We believe that using open-ended questions in the interview-guide allowed the participants to share real-life experiences, and this contributes to validating the results for the sample.
Conclusions
Pregnant WWE were confident in using AEDs to avoid seizures, although dose adjustments associated with pregnancy increased perceived risks of teratogenicity or seizures. The women were satisfied with the follow-up and medicines information provided, and physicians, in particular neurologists, were regarded as highly trusted providers of medicines information. We suggest the following possible strategies for medicines information to pregnant WWE. Some of these strategies may also be relevant for medicines information to pregnant women with other chronic diseases.
Explain the need for, and consequences of, dose adjustments of AEDs during and after pregnancy to reduce unnecessary concerns. Provide balanced presentations of benefits and risks, both of AEDs and other medicines to achieve satisfactory health of mother and foetus. Arrange support groups where WWE who have experienced a normal pregnancy while using AEDs can support and discuss risk perception with nulliparous WWE. Offer individually tailored medicines information, preferentially by the neurologist, and allocate sufficient time to answer questions.
